{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:33Z","timestamp":1772119473867,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802636"],"award-info":[{"award-number":["81802636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LinGang laboratory","award":["LG-QS-202205-11"],"award-info":[{"award-number":["LG-QS-202205-11"]}]},{"name":"Industry-University Research Innovation Fund of Science and Technology Development Center of the Ministry of Education","award":["2021JH013"],"award-info":[{"award-number":["2021JH013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sentinel node biopsy (SNB) has become a critical part of standard surgical treatment for melanoma with no clinical metastatic evidence. However, for patients with a positive sentinel node, the MSLT-II and DeCOG-SLT trials have shown that immediate complete lymph node dissection (CLND) does not bring further survival benefits. There is still an argument among the Chinese population dominated by acral subtypes on whether CLND can be omitted. Thus, this study aims to investigate the impact of immediate CLND on relapse-free survival (RFS) in Chinese melanoma patients with a positive sentinel node. Patients with acral or cutaneous melanoma of clinical Stages I\u2013II who received SNB procedure and were detected with nodal micrometastasis were retrospectively collected at Fudan University Cancer Center (FUSCC) from January 2017 to December 2021. The clinicopathologic features and prognostic factors for RFS were analyzed. Out of 381 patients who received SNB in the past 5 years, 130 (34%) cases with SN micrometastasis detected were included in this study. Ninety-nine patients underwent immediate CLND while the other 31 patients received observation alone. Among patients who received CLND, the non-SN(NSN)-positive rate was 22.2%. Most of the clinicopathologic factors were balanced well between the CLND and non-CLND groups. However, more patients in the CLND group were detected with BRAF and NRAS mutation (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.006) and received adjuvant PD-1 monotherapy (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.042) as well. There were slightly fewer N1 patients in the CLND group, although the difference did not reach statistical significance (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.075). The study found no significant difference in RFS between the two groups (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.184). Even for patients with the acral subtype (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.925), primary T4 lesion (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.769), or presence of ulceration (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.249), immediate CLND did not bring more survival benefits. Immediate CLND did not bring further RFS benefit for Chinese melanoma patients with SN micrometastasis in real-world clinical practice, even for patients with acral subtype or more tumor burden such as thick Breslow invasion and ulceration.\n                  <\/jats:p>","DOI":"10.1007\/s10238-023-01107-z","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T02:01:38Z","timestamp":1686362498000},"page":"4003-4010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Survival impact of immediate complete lymph node dissection for Chinese acral and cutaneous melanoma with micrometastasis in sentinel nodes: a retrospective study"],"prefix":"10.1007","volume":"23","author":[{"given":"Jingqin","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"issue":"7","key":"1107_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1310460.","journal-title":"N Engl J Med"},{"issue":"23","key":"1107_CR2","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1613210.","journal-title":"N Engl J Med"},{"issue":"32","key":"1107_CR3","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000\u20138. https:\/\/doi.org\/10.1200\/JCO.18.02306.","journal-title":"J Clin Oncol"},{"key":"1107_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2022. Eur J Cancer. 2022;170:256\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.018.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1107_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","volume":"19","author":"SM Swetter","year":"2021","unstructured":"Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021. J Natl Compr Canc Netw. 2021;19(4):364\u201376. https:\/\/doi.org\/10.6004\/jnccn.2021.0018.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1107_CR6","first-page":"81","volume":"42","author":"Soft Tissue Tumor and Melanoma Group of Sarcoma Committee, Chinese Anti-Cancer Association","year":"2020","unstructured":"Soft Tissue Tumor and Melanoma Group of Sarcoma Committee, Chinese Anti-Cancer Association. Chinese expert consensus on the surgical treatment of cutaneous\/acral melanoma V1.0. Zhonghua Zhong Liu Za Zhi. 2020;42(2):81\u201393.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"9","key":"1107_CR7","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1245\/s10434-020-08418-5","volume":"27","author":"X Wei","year":"2020","unstructured":"Wei X, Wu D, Li H, et al. The clinicopathological and survival profiles comparison across primary sites in acral melanoma. Ann Surg Oncol. 2020;27(9):3478\u201385. https:\/\/doi.org\/10.1245\/s10434-020-08418-5.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1107_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1203475418800943","volume":"23","author":"LS Lino-Silva","year":"2019","unstructured":"Lino-Silva LS, Zepeda-Najar C, Salcedo-Hern\u00e1ndez RA, Mart\u00ednez-Said H. Acral lentiginous melanoma: survival analysis of 715 cases. J Cutan Med Surg. 2019;23(1):38\u201343. https:\/\/doi.org\/10.1177\/1203475418800943.","journal-title":"J Cutan Med Surg"},{"key":"1107_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jss.2020.02.010","volume":"251","author":"K Huang","year":"2020","unstructured":"Huang K, Fan J, Misra S. Acral lentiginous melanoma: incidence and survival in the United States, 2006\u20132015, an analysis of the SEER Registry. J Surg Res. 2020;251:329\u201339. https:\/\/doi.org\/10.1016\/j.jss.2020.02.010.","journal-title":"J Surg Res"},{"issue":"11","key":"1107_CR10","first-page":"819","volume":"28","author":"Y Xu","year":"2018","unstructured":"Xu Y, Zhu H, Chen Y, et al. The clinical significance of sentinel lymph node biopsy in the Chinese patients with cutaneous and acral melanoma. China Oncol. 2018;28(11):819\u201326.","journal-title":"China Oncol"},{"issue":"5","key":"1107_CR11","first-page":"360","volume":"47","author":"M Ren","year":"2018","unstructured":"Ren M, Kong YY, Cai X, Shen XX, Lyu JJ. Application of sentinel lymph node biopsy in patients with melanoma. Zhonghua Bing Li Xue Za Zhi. 2018;47(5):360\u20135.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"3","key":"1107_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jaad.2020.07.113","volume":"84","author":"ME Burnett","year":"2021","unstructured":"Burnett ME, Brodland DG, Zitelli JA. Long-term outcomes of Mohs micrographic surgery for invasive melanoma of the trunk and proximal portion of the extremities. J Am Acad Dermatol. 2021;84(3):661\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.113.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1107_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00533.","journal-title":"J Clin Oncol"},{"key":"1107_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejca.2022.06.041","volume":"173","author":"J Larkin","year":"2022","unstructured":"Larkin J, Weber J, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer. 2022;173:285\u201396. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.041.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1107_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/jso.26736","volume":"125","author":"B Rentroia-Pacheco","year":"2022","unstructured":"Rentroia-Pacheco B, Tjien-Fooh FJ, Quattrocchi E, et al. Clinicopathologic models predicting non-sentinel lymph node metastasis in cutaneous melanoma patients: are they useful for patients with a single positive sentinel node? J Surg Oncol. 2022;125(3):516\u201324. https:\/\/doi.org\/10.1002\/jso.26736.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1107_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00403-021-02232-z","volume":"314","author":"L Loidi-Pascual","year":"2022","unstructured":"Loidi-Pascual L, Librero J, C\u00f3rdoba-Iturriagagoitia A, et al. Sentinel node tumor burden in cutaneous melanoma. Survival with competing risk analysis and influence in relapses and non-sentinel node status: retrospective cohort study with long follow-up in a Spanish population [published correction appears in Arch Dermatol Res. 2021 Nov 23]. Arch Dermatol Res. 2022;314(4):369\u201378. https:\/\/doi.org\/10.1007\/s00403-021-02232-z.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1107_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ejso.2022.01.021","volume":"48","author":"AJ Cochran","year":"2022","unstructured":"Cochran AJ, Wen DR, Huang RR, et al. Sentinel lymph node melanoma metastases: assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Eur J Surg Oncol. 2022;48(6):1280\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2022.01.021.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"1107_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/ijd.15594","volume":"60","author":"A Yousaf","year":"2021","unstructured":"Yousaf A, Tjien-Fooh FJ, Rentroia-Pacheco B, et al. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study. Int J Dermatol. 2021;60(7):851\u20136. https:\/\/doi.org\/10.1111\/ijd.15594.","journal-title":"Int J Dermatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01107-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01107-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01107-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T16:20:04Z","timestamp":1698769204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01107-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01107-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2888154\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of  interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of FUSCC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}